Acorah Software Products - Accounts Production 15.0.310 false true false 16 March 2023 31 March 2024 31 March 2024 SC762525 Miss Sehar Shahid Mr Usmaan Shahid iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure SC762525 2023-03-15 SC762525 2024-03-31 SC762525 2023-03-16 2024-03-31 SC762525 frs-core:CurrentFinancialInstruments 2024-03-31 SC762525 frs-core:Non-currentFinancialInstruments 2024-03-31 SC762525 frs-core:ComputerEquipment 2024-03-31 SC762525 frs-core:ComputerEquipment 2023-03-16 2024-03-31 SC762525 frs-core:ComputerEquipment 2023-03-15 SC762525 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-03-16 2024-03-31 SC762525 frs-core:FurnitureFittings 2024-03-31 SC762525 frs-core:FurnitureFittings 2023-03-16 2024-03-31 SC762525 frs-core:FurnitureFittings 2023-03-15 SC762525 frs-core:OtherResidualIntangibleAssets 2024-03-31 SC762525 frs-core:OtherResidualIntangibleAssets 2023-03-16 2024-03-31 SC762525 frs-core:OtherResidualIntangibleAssets 2023-03-15 SC762525 frs-core:ShareCapital 2024-03-31 SC762525 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31 SC762525 frs-bus:PrivateLimitedCompanyLtd 2023-03-16 2024-03-31 SC762525 frs-bus:FilletedAccounts 2023-03-16 2024-03-31 SC762525 frs-bus:SmallEntities 2023-03-16 2024-03-31 SC762525 frs-bus:AuditExempt-NoAccountantsReport 2023-03-16 2024-03-31 SC762525 frs-bus:SmallCompaniesRegimeForAccounts 2023-03-16 2024-03-31 SC762525 frs-bus:Director1 2023-03-16 2024-03-31 SC762525 frs-bus:Director2 2023-03-16 2024-03-31 SC762525 frs-countries:Scotland 2023-03-16 2024-03-31
Registered number: SC762525
Next Gen Pharma Ltd
Unaudited Financial Statements
For the Period 16 March 2023 to 31 March 2024
TaxAssist Accountants
Unaudited Financial Statements
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: SC762525
31 March 2024
Notes £ £
FIXED ASSETS
Intangible Assets 4 25,906
Tangible Assets 5 14,199
40,105
CURRENT ASSETS
Debtors 6 6,605
Cash at bank and in hand 19,759
26,364
Creditors: Amounts Falling Due Within One Year 7 (115,976 )
NET CURRENT ASSETS (LIABILITIES) (89,612 )
TOTAL ASSETS LESS CURRENT LIABILITIES (49,507 )
Creditors: Amounts Falling Due After More Than One Year 8 (38,158 )
NET LIABILITIES (87,665 )
CAPITAL AND RESERVES
Called up share capital 9 1
Profit and Loss Account (87,666 )
SHAREHOLDERS' FUNDS (87,665)
Page 1
Page 2
For the period ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Miss Sehar Shahid
Director
15/08/2024
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Next Gen Pharma Ltd is a private company, limited by shares, incorporated in Scotland, registered number SC762525 . The registered office is Studio 5 Sir James Clark Building, Abbey Mill Business Centre, Paisley, PA1 1TJ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are .... It is amortised to profit and loss account over its estimated economic life of .... years.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Fixtures & Fittings Reducing balance method
Computer Equipment Reducing balance method
3. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
4. Intangible Assets
Other
£
Cost
As at 16 March 2023 -
Additions 30,478
As at 31 March 2024 30,478
Amortisation
As at 16 March 2023 -
Provided during the period 4,572
As at 31 March 2024 4,572
Net Book Value
As at 31 March 2024 25,906
As at 16 March 2023 -
5. Tangible Assets
Fixtures & Fittings Computer Equipment Total
£ £ £
Cost
As at 16 March 2023 - - -
Additions 15,367 2,857 18,224
As at 31 March 2024 15,367 2,857 18,224
...CONTINUED
Page 3
Page 4
Depreciation
As at 16 March 2023 - - -
Provided during the period 3,073 952 4,025
As at 31 March 2024 3,073 952 4,025
Net Book Value
As at 31 March 2024 12,294 1,905 14,199
As at 16 March 2023 - - -
6. Debtors
31 March 2024
£
Due within one year
Prepayments and accrued income 2,778
Other debtors 1,752
VAT 2,075
6,605
7. Creditors: Amounts Falling Due Within One Year
31 March 2024
£
Trade creditors 4,933
Bank loans and overdrafts 9,907
Other taxes and social security 13
Other creditors 46
Directors' loan accounts 72,587
Amounts owed to associates 28,490
115,976
8. Creditors: Amounts Falling Due After More Than One Year
31 March 2024
£
Bank loans 38,158
38,158
9. Share Capital
31 March 2024
£
Allotted, Called up and fully paid 1
Page 4